148.00
+2.42%
Close of 9 Nov 2026, in TWD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Ever Supreme Bio Technology Co
Its shares trade on Taipei Exchange under the ticker 6712.TWO. It has been listed since 26 October 2018. In the fiscal year to 31 December 2025, it reported revenue of TWD 1.02bn and net income of TWD 429.4m. At that date it held total assets of TWD 2.00bn and shareholders' equity of TWD 1.53bn.
Ever Supreme Bio Technology Co., Ltd. engages in the research, development, and sale of stem cell products. The company is headquartered in Taichung, Taichung. The company went IPO on 2018-10-26. The firm has three main products. ADCV01 is an autologous dendritic cell tumor vaccine product, which is currently in the phaseII of clinical trials in Taiwan. UMSC01 is a human allogeneic umbilical cord stem cell product and a new drug for the treatment of myocardial infarction, which is approved by the United States Food and Drug Administration (FDA) clinical phaseI and is currently applying for the phaseI of clinical trials in Taiwan. UMSC01 is a human allogeneic umbilical cord stem cell product, which is used to treat acute ischemic stroke and is currently in the United States FDA for clinical phase I. The firm plans to develop new products and services including mesenchymal stem cells for the treatment of multiple sclerosis.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 26 Oct 2018
- Employees
- 8
- Website
- ever-supreme.com.tw ↗
Leadership
Pay as last reported
- Mr. Zhuqi LiuChairman of the Board, since 2016TWD 21,000
- Mr. Baiqin LiFinance Manager
- Mr. Wen-Liang HuangGeneral Manager, Director, since 2017TWD 8.8m
- Mr. Woei-Cheang ShyuDeputy General Manager-Research & DevelopmentTWD 2.2m
- Mr. Shih-Chinn HoDirector
- Mr. Jinlong ChenIndependent DirectorTWD 372,000
- Mr. Wenhou ChenIndependent DirectorTWD 381,000
- Mr. Hui-Ming LuIndependent DirectorTWD 378,000
- Ms. Jinting XuManager-Project Management Division, since 2022
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Ever Supreme Bio Technology Co Ltd has three main products including ADCV01 and UMSC01 in clinical trials.
- The company's UMSC01 product is approved by the FDA for clinical phase I in the United States.
- Ever Supreme Bio Technology Co Ltd is developing mesenchymal stem cells for multiple sclerosis treatment.
Weaknesses
- The company has only eight employees which may limit its operational capacity.
- Ever Supreme Bio Technology Co Ltd is based in Taichung, Taiwan, which may restrict market access.
- The firm's products are still in clinical trials phase II and phase I in Taiwan.
Opportunities
- The FDA approval for UMSC01 in the United States opens new market opportunities.
- The company plans to develop new products for multiple sclerosis treatment.
- Ever Supreme Bio Technology Co Ltd can expand its clinical trials in Taiwan for UMSC01.
Threats
- The company's products are in early clinical trial stages which pose regulatory risks.
- Ever Supreme Bio Technology Co Ltd faces competition from other biotechnology firms in Taiwan.
- The firm's limited employee count may hinder its ability to meet market demands.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.